CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in...
Read MoreCatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO
CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase...
Read MoreCatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in...
Read MoreCatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO
CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial...
Read MoreCatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development
CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development Experienced...
Read MoreCatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025
CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug...
Read MoreCatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical...
Read MoreCatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature
CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to...
Read MoreCatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference
CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD...
Read MoreCatalYm Announces Leadership Change
CatalYm Announces Leadership Change Munich, Germany, October 11, 2024 – CatalYm...
Read More